<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Topical skin-lightening agents: Complications of use in the nonmedical setting</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Topical skin-lightening agents: Complications of use in the nonmedical setting</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Topical skin-lightening agents: Complications of use in the nonmedical setting</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Andrew F Alexis, MD, MPH</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Jeffrey S Dover, MD, FRCPC</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Abena O Ofori, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> May 13, 2022.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H222412565"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Skin-lightening (or "skin-bleaching") agents are essential tools in the management of disorders of hyperpigmentation, such as melasma and postinflammatory hyperpigmentation. However, some skin-lightening practices and ingredients can result in multiple short- and long-term complications. Examples include irritant contact dermatitis, exogenous ochronosis, mercury toxicity, cutaneous atrophy, and adrenal insufficiency.</p><p>The availability of skin-lightening formulations that are not regulated, that contain ingredients that are illegal to sell without a prescription, or that contain ingredients not intended for cutaneous use contributes to the development of complications. Adverse events may also result from prolonged or excessive use of approved skin-lightening formulations.</p><p>Early recognition of signs associated with skin-lightening agent misuse is important in reducing long-term sequelae. The complications associated with misuse of skin-lightening agents will be reviewed here. Prescribed use of skin-lightening agents for the treatment of cutaneous hyperpigmentation is reviewed separately. (See  <a class="medical medical_review" href="/d/html/6621.html" rel="external">"Melasma: Management"</a> and  <a class="medical medical_review" href="/d/html/95847.html" rel="external">"Postinflammatory hyperpigmentation", section on 'Medical treatment'</a>.)</p><p class="headingAnchor" id="H2454594093"><span class="h1">PREVALENCE OF SKIN LIGHTENING</span><span class="headingEndMark"> — </span>Skin lightening is a global phenomenon, with the highest rates in Africa, Asia, the Caribbean, and the Middle East, as well as in immigrant populations from these regions in North America and Europe [<a href="#rid1">1-6</a>].</p><p>Studies in some populations have reported relatively high rates of use of skin-lightening agents; for example, a South African survey of female patients (Fitzpatrick skin phototype IV or higher (<a class="graphic graphic_table graphicRef60541" href="/d/graphic/60541.html" rel="external">table 1</a>)) who visited two general outpatient hospital departments in Durban found that 187 of 571 (33 percent) reported use of skin-lightening products. In addition, a Ghanaian study of 555 individuals (primarily female) in fishing communities in Accra found a prevalence of use of skin-lightening products of 50 percent [<a href="#rid4">4,5</a>]. Reports from Asia, North America, Europe, and Latin America have also demonstrated complications associated with skin-lightening agents in populations where the practice is prevalent [<a href="#rid1">1,3,7-12</a>].</p><p class="headingAnchor" id="H1977487244"><span class="h1">MOTIVATION FOR SKIN LIGHTENING</span><span class="headingEndMark"> — </span>The skin-lightening industry is a multibillion dollar industry [<a href="#rid13">13,14</a>]. The industry encompasses both use for the treatment of pigmentary disorders and use for the purpose of lightening natural skin pigmentation, with geographic variance in the proportions associated with these indications [<a href="#rid6">6</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Cultural and commercial beauty ideals</strong> – The widespread practice of skin lightening stems from cultural and commercial beauty ideals, many of which are propagated by media using local models with lightly pigmented skin [<a href="#rid15">15,16</a>]. In numerous cultures, less skin pigmentation is frequently equated with higher social status and physical attractiveness due, at least in part, to complex, historical, sociopolitical factors.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Social factors</strong> – Certain social factors may influence the likelihood of skin-lightening practices. A questionnaire-based study of skin-lightening practices among 76 female adults in New York City who had utilized skin-lightening products for at least one year found associations between certain social factors and the intensity of skin-lightening practices [<a href="#rid12">12</a>]. In particular, female adults with lower education status and females who were born outside of the United States were more likely to report a longer duration of skin-lightening practices and daily use of skin-lightening products.</p><p></p><p class="bulletIndent1">Influence from close personal relationships may contribute to skin-lightening practices. A survey of 348 undergraduate females in Sudan found that the women were more likely to engage in skin lightening if a family member engaged in skin lightening or if they were dissatisfied with skin color [<a href="#rid17">17</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Psychologic factors</strong> – A questionnaire-based study of 1226 young adults from Jamaica, Barbados, and Grenada found associations between use of skin-lightening agents and a history of abuse as a child, symptoms of trauma, and significant depression [<a href="#rid18">18</a>].</p><p></p><p class="headingAnchor" id="H1314835831"><span class="h1">AGENTS</span><span class="headingEndMark"> — </span>Skin-lightening agents commonly found in regulated and unregulated skin-lightening products that can cause complications include <a class="drug drug_general" data-topicid="8539" href="/d/drug information/8539.html" rel="external">hydroquinone</a>, corticosteroids, mercury salts, and caustic agents:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Mechanisms of action</strong> – The mechanism of action of <a class="drug drug_general" data-topicid="8539" href="/d/drug information/8539.html" rel="external">hydroquinone</a> involves inhibition of tyrosinase activity, which inhibits the conversion of dihydroxyphenylalanine to melanin. Topical corticosteroids and mercury salts have inhibitory effects on melanogenesis [<a href="#rid1">1</a>]. Caustic agents such as <a class="drug drug_general" data-topicid="113931" href="/d/drug information/113931.html" rel="external">hydrogen peroxide</a> may inhibit melanin production through toxic effects on melanocytes.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Availability</strong> – In the United States, products that contain skin-lightening agents, such as <a class="drug drug_general" data-topicid="8539" href="/d/drug information/8539.html" rel="external">hydroquinone</a> and topical corticosteroids, are legally available as both prescription and nonprescription products. When used appropriately, risk for complications from such agents is low.</p><p></p><p class="bulletIndent1">However, unregulated skin-lightening products that contain unapproved ingredients or unapproved concentrations of ingredients can be obtained without a prescription in the United States and other countries. These products are typically purchased from small convenience stores, cosmetic shops, and street vendors [<a href="#rid4">4</a>]. In the United States, such products are usually imported by international companies or smuggled into areas where the demand is high [<a href="#rid19">19</a>]. Skin-lightening formulations containing unregulated ingredients can also be purchased via the internet worldwide.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Inaccurate product labeling and inclusion of caustic substances</strong> – Clinicians should be aware that ingredient lists provided on or in packages of skin-lightening agents are not always accurate. A study examining the active ingredients in the 10 best-selling skin-lightening creams in Durban, South Africa, found that nearly one-half of the analyzed products contained mercury as an active ingredient, although this was not listed on the label or package insert [<a href="#rid20">20</a>].</p><p></p><p class="bulletIndent1">In addition, according to the US Food and Drug Administration, cosmetics and skin-bleaching preparations should contain no more than a trace amount of mercury, defined as less than 1 part per million (ppm) [<a href="#rid21">21</a>]. However, concentrations well above this limit have been found in numerous skin-lightening creams sold in the United States and internationally. In one study of 549 skin-lightening products, 6 percent contained mercury above 1000 ppm [<a href="#rid22">22</a>]. Moreover, a study assessing mercury concentrations in spot urine specimens from a representative sample of 1840 adult New Yorkers found that mercury-containing skin-lightening creams were a source of exposure in individuals with the highest levels of mercury in the urine [<a href="#rid23">23</a>].</p><p></p><p class="bulletIndent1">In some instances (particularly in sub-Saharan Africa), ingredients from the domestic environment (toothpaste, washing liquid, washing soda, hair straighteners, sand, cement, and even battery fluid) are mixed in homemade skin-bleaching concoctions for their caustic effect [<a href="#rid1">1,20,24</a>].</p><p></p><p class="headingAnchor" id="H4033049521"><span class="h1">COMPLICATIONS</span><span class="headingEndMark"> — </span>Misuse of skin-lightening agents can result in a variety of local and systemic adverse effects. Adverse effects related to <a class="drug drug_general" data-topicid="8539" href="/d/drug information/8539.html" rel="external">hydroquinone</a>, mercury, and topical corticosteroids in skin-lightening agents are reviewed below.</p><p class="headingAnchor" id="H3906387504"><span class="h2">Hydroquinone</span><span class="headingEndMark"> — </span>While <a class="drug drug_general" data-topicid="8539" href="/d/drug information/8539.html" rel="external">hydroquinone</a> is a safe and effective treatment for a broad range of disorders of hyperpigmentation, risk for acute and chronic complications increases in association with protracted administration, use of high concentrations, mixture with other ingredients that enhance dermal absorption (eg, resorcinol), and application to large body surface areas. Potential complications include short-term cutaneous side effects, exogenous ochronosis, abnormal skin repigmentation, darker pigmentation of skin overlying finger and toe joints, and trimethylaminuria.</p><p class="headingAnchor" id="H3207892911"><span class="h3">Short-term cutaneous complications</span><span class="headingEndMark"> — </span>Irritant contact dermatitis, typically from concentrations higher than 4 percent or when mixed with caustic additives to increase absorption, is the most common short-term adverse event associated with <a class="drug drug_general" data-topicid="8539" href="/d/drug information/8539.html" rel="external">hydroquinone</a> and may result in postinflammatory dyspigmentation. Hydroquinone may also induce allergic contact dermatitis [<a href="#rid25">25</a>].</p><p class="headingAnchor" id="H3905541245"><span class="h3">Exogenous ochronosis</span><span class="headingEndMark"> — </span>Excessive or long-term use of <a class="drug drug_general" data-topicid="8539" href="/d/drug information/8539.html" rel="external">hydroquinone</a> can lead to exogenous ochronosis:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical manifestations</strong> – Exogenous ochronosis most often manifests as asymptomatic, blue-black macules and patches, most commonly on the cheeks, temples, and neck (<a class="graphic graphic_picture graphicRef90021 graphicRef111604 graphicRef111605" href="/d/graphic/90021.html" rel="external">picture 1A-C</a>) [<a href="#rid26">26</a>]. Three clinical stages of exogenous ochronosis have been described: erythema and mild pigmentation; hyperpigmentation, black colloid milia, and scanty atrophy; and papulonodules with or without surrounding inflammation [<a href="#rid27">27</a>]. Unlike its endogenous form (alkaptonuria), exogenous ochronosis lacks any systemic complications or urinary abnormalities. (See  <a class="medical medical_review" href="/d/html/2935.html" rel="external">"Disorders of tyrosine metabolism", section on 'Alkaptonuria'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Diagnosis</strong> – The pathogenesis of exogenous ochronosis may involve inhibition of homogentisic acid oxidase leading to the accumulation of homogentisic acid in the skin, which then polymerizes to form the ochronotic deposits in the dermis [<a href="#rid26">26</a>]. A skin biopsy (eg, 3 or 4 mm punch biopsy) demonstrating yellow-brown, banana-shaped fibers in the papillary dermis is the gold standard for diagnosis (<a class="graphic graphic_picture graphicRef100568" href="/d/graphic/100568.html" rel="external">picture 2</a>). The ochronotic fibers stain black with Fontana stain and blue-black with <a class="drug drug_general" data-topicid="9636" href="/d/drug information/9636.html" rel="external">methylene blue</a> stain [<a href="#rid26">26,28</a>]. Dermoscopy can also be a useful diagnostic tool; amorphous, densely pigmented structures obliterating follicular openings can be observed [<a href="#rid29">29,30</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Management</strong> – Exogenous ochronosis may improve slowly after stopping the offending lightening agent [<a href="#rid31">31</a>] but is generally considered permanent. There have been positive results with quality-switched (Q-switched) ruby laser, 755 nm Q-switched alexandrite laser, combination dermabrasion plus carbon dioxide (CO<sub>2</sub>) laser, 1064 nm neodymium-doped yttrium aluminum garnet (Nd:YAG) laser, and cryotherapy [<a href="#rid26">26,32-34</a>]. Other studies have shown no improvement [<a href="#rid29">29,32</a>]. In the author's experience, nonablative fractional laser resurfacing can improve the appearance of exogenous ochronosis but can induce postinflammatory hyperpigmentation. Topical retinoic acid and combination treatments including retinoic acid have been attempted with mixed results [<a href="#rid7">7,29,35</a>].</p><p></p><p class="headingAnchor" id="H481122016"><span class="h3">Other side effects</span><span class="headingEndMark"> — </span>Additional potential side effects of <a class="drug drug_general" data-topicid="8539" href="/d/drug information/8539.html" rel="external">hydroquinone</a> misuse include:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Abnormal skin repigmentation</strong> – Abnormal repigmentation of skin can occur, particularly in sun-exposed areas. This typically manifests as mottled hyperpigmentation on the malar area, dorsal extremities, and/or upper trunk.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Hyperpigmentation of the finger joints and toes</strong> – Hyperpigmentation of the finger joints (especially the distal and proximal interphalangeal joints) and toes relative to the dorsal hands and feet is a common sequela of skin bleaching of the hands and feet with <a class="drug drug_general" data-topicid="8539" href="/d/drug information/8539.html" rel="external">hydroquinone</a> [<a href="#rid36">36</a>]. This likely represents residual, normal pigmentation as opposed to increased pigment production.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Nail discoloration</strong> – Brown or orange-brown discoloration of the fingernails resulting from direct contact of the nails with <a class="drug drug_general" data-topicid="8539" href="/d/drug information/8539.html" rel="external">hydroquinone</a> has been described [<a href="#rid37">37,38</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Trimethylaminuria</strong> – Trimethylaminuria, also known as "fish odor syndrome," has been reported among chronic users of skin-bleaching creams containing <a class="drug drug_general" data-topicid="8539" href="/d/drug information/8539.html" rel="external">hydroquinone</a>. This is characterized by a rotten fish odor in the breath, urine, and body due to excretion of trimethylamine in body fluids [<a href="#rid19">19</a>].</p><p></p><p class="headingAnchor" id="H548041556"><span class="h2">Mercury</span><span class="headingEndMark"> — </span>Complications of exposure to mercury through misuse of skin-lightening agents include cutaneous, renal, and neuropsychiatric abnormalities [<a href="#rid22">22</a>].</p><p class="headingAnchor" id="H3250833863"><span class="h3">Cutaneous complications</span><span class="headingEndMark"> — </span>Cutaneous complications of mercury-containing skin-lightening formulations include contact dermatitis, erythroderma, flushing, purpura, gingivostomatitis, gray or blue-black facial discoloration (paradoxical hyperpigmentation) secondary to dermal deposition of mercury-containing granules, and nail discoloration [<a href="#rid25">25,39</a>].</p><p class="headingAnchor" id="H1994755048"><span class="h3">Mercury toxicity</span><span class="headingEndMark"> — </span>Systemic exposure to inorganic mercury or mercury salts can occur as a result of cutaneous absorption or inadvertent oral ingestion (eg, from use of mercury-containing cosmetics near the mouth or from hand-to-mouth contact) [<a href="#rid40">40</a>]. The rate of dermal absorption of inorganic mercury is proportional to the concentration of mercury and prior hydration of the skin. Dermal absorption is increased when mercury-containing cosmetics are formulated in lipid-soluble vehicles or applied to compromised skin [<a href="#rid40">40</a>].</p><p>Once absorbed, inorganic mercury is distributed widely and is eliminated primarily through urinary excretion and the feces [<a href="#rid40">40</a>]. Systemic complications include proteinuria, nephrotic syndrome, renal tubular acidosis, tremor, muscle weakness, peripheral neuropathy, metallic taste, hypersalivation, memory loss, erethism, depression, anxiety, and psychosis (eg, "mad hatter's disease") [<a href="#rid8">8,13,25,39,41-43</a>]. Mercury exposure during pregnancy may adversely affect neurologic and cognitive development of the fetus [<a href="#rid44">44</a>]. The manifestations, diagnosis, and management of mercury toxicity are reviewed in detail separately. (See  <a class="medical medical_review" href="/d/html/7179.html" rel="external">"Mercury toxicity", section on 'Inorganic mercury salts toxicity'</a>.)</p><p class="headingAnchor" id="H1055595164"><span class="h2">Topical corticosteroids</span><span class="headingEndMark"> — </span>Use of skin-lightening creams that contain corticosteroids, particularly unregulated formulations containing high-potency agents such as <a class="drug drug_general" data-topicid="9276" href="/d/drug information/9276.html" rel="external">clobetasol</a> propionate, <a class="drug drug_general" data-topicid="8460" href="/d/drug information/8460.html" rel="external">fluocinonide</a>, and <a class="drug drug_general" data-topicid="9139" href="/d/drug information/9139.html" rel="external">betamethasone</a> dipropionate, can lead to adverse cutaneous and systemic effects. Patients are typically unaware that their skin-lightening products contain corticosteroids; therefore, recognition of the characteristic signs and symptoms of corticosteroid excess is critical for diagnosis.</p><p class="headingAnchor" id="H1627042059"><span class="h3">Cutaneous complications</span><span class="headingEndMark"> — </span>Common cutaneous manifestations of long-term use of skin-lightening agents containing corticosteroids include atrophy, striae, folliculitis (especially near the axillae), acne, tinea corporis, hypertrichosis, purpura, hypopigmentation, and persistent erythema (<a class="graphic graphic_picture graphicRef121535" href="/d/graphic/121535.html" rel="external">picture 3</a>) [<a href="#rid19">19,36</a>]. In particular, tinea corporis may be extensive and may present with an atypical appearance (tinea incognito). (See  <a class="medical medical_review" href="/d/html/5565.html" rel="external">"Topical corticosteroids: Use and adverse effects", section on 'Adverse effects'</a>.)</p><p class="headingAnchor" id="H789710455"><span class="h3">Systemic complications</span><span class="headingEndMark"> — </span>Prolonged administration of topical corticosteroids and application to large body surface areas increases the risk for systemic absorption and associated complications. Systemic complications of corticosteroid-containing skin-lightening creams, particularly when used for large-scale skin lightening, include hyperglycemia, hypothalamic-pituitary-adrenal axis suppression, Cushing's syndrome, hypertension, and avascular necrosis of the femoral head [<a href="#rid19">19,36,45,46</a>]. (See  <a class="medical medical_review" href="/d/html/5565.html" rel="external">"Topical corticosteroids: Use and adverse effects", section on 'Adverse effects'</a>.)</p><p class="headingAnchor" id="H1270361526"><span class="h1">PATIENT EVALUATION AND MANAGEMENT</span><span class="headingEndMark"> — </span>Cultural sensitivity is paramount when asking patients about use of skin-lightening agents and recommending their discontinuation.</p><p class="headingAnchor" id="H1066841279"><span class="h2">Recognition of at-risk patients</span><span class="headingEndMark"> — </span>Early recognition of use of skin-lightening agents is important for minimizing risk for complications.</p><p>Examples of incidental physical findings that raise suspicion for use of skin-lightening agents include:</p><p class="bulletIndent1"><span class="glyph">●</span>A paradoxically lighter appearance of the face compared with sun-protected areas</p><p class="bulletIndent1"><span class="glyph">●</span>Islands of normal pigment over the joints in the context of diffuse lightening of the hands</p><p></p><p>Commonly, patients present with signs of cutaneous or systemic complications that lead to recognition of skin-lightening agent use (eg, skin darkening related to <a class="drug drug_general" data-topicid="8539" href="/d/drug information/8539.html" rel="external">hydroquinone</a>, acne exacerbations or striae related to topical corticosteroids, or systemic symptoms). (See <a class="local">'Hydroquinone'</a> above and <a class="local">'Mercury'</a> above and <a class="local">'Topical corticosteroids'</a> above.)</p><p class="headingAnchor" id="H3864910679"><span class="h2">Confirming use of skin-lightening agents</span><span class="headingEndMark"> — </span>Recognizing that there are cultural factors, individual factors, and potential feelings of shame associated with the practice of skin lightening, the patient interview should be conducted with sensitivity. Directly asking if a patient is "bleaching their skin" or "trying to lighten their skin color" may be perceived as judgemental or confrontational. Use of open-ended and nonjudgmental questions is preferred. Examples include:</p><p class="bulletIndent1"><span class="glyph">●</span>"For accurate diagnosis, it is helpful to know all of the products you have used on your skin in the past year or so. Can we review all of the skin care products you are using, even those you only use occasionally?"</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>"Some skin care products include ingredients that can cause this problem on the skin. So that I can be the most helpful, can we review all of the products you are using on your skin?"</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>"Does your skin care routine include any products to help even out your skin tone, brighten your skin, or improve the appearance of your skin?"</p><p></p><p>Asking the patient to bring all of their skin care products to the next appointment is also helpful, if feasible.</p><p class="headingAnchor" id="H3779578954"><span class="h2">Interventions</span><span class="headingEndMark"> — </span>The goal of intervention is to minimize risk from adverse effects associated with prolonged use of skin-lightening agents. Key interventions include patient counseling to encourage cessation of misuse and the management of complications.</p><p class="headingAnchor" id="H2383661215"><span class="h3">Patient counseling</span><span class="headingEndMark"> — </span>Once use of a skin-lightening agent has been determined, we encourage cessation of use and counsel patients on the potential adverse local and systemic effects of excessive or protracted use of skin-lightening agents, especially unregulated formulations. Sensitivity is important. We find the following approaches helpful for preserving the clinician-patient relationship and increasing the likelihood of adherence to clinician recommendations:</p><p class="bulletIndent1"><span class="glyph">●</span>Avoid assigning or implying blame on the patient or challenging their personal beauty ideals</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Discuss the shared goal of ensuring long-term skin health and preventing adverse effects in a nonjudgmental manner</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Make an effort to understand the patient's aesthetic goals or concerns</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Offer safer therapies for specific skin concerns or underlying skin disorders</p><p></p><p class="headingAnchor" id="H4214205279"><span class="h3">Assessment for mercury toxicity</span><span class="headingEndMark"> — </span>Given the potential serious complications of mercury exposure, an assessment for mercury toxicity is indicated for all patients with a history of excessive use of unregulated skin-lightening agents (eg, use on a large proportion of the body surface area or prolonged use). If the clinical presentation or a review of systems suggests the possibility of mercury toxicity, further evaluation is indicated. (See <a class="local">'Mercury toxicity'</a> above and  <a class="medical medical_review" href="/d/html/7179.html" rel="external">"Mercury toxicity", section on 'Diagnosis'</a> and  <a class="medical medical_review" href="/d/html/7179.html" rel="external">"Mercury toxicity", section on 'Clinical manifestations'</a>.)</p><p class="headingAnchor" id="H3656396556"><span class="h3">Management of complications</span><span class="headingEndMark"> — </span>Cessation of use of the skin-lightening agent is often the most important factor in minimizing progression of complications and improving reversible complications. (See <a class="local">'Complications'</a> above.)</p><p>Specific additional interventions may be helpful for some complications, such as antifungal therapy for corticosteroid-related tinea infections, laser therapy for exogenous ochronosis, or interventions for mercury toxicity. (See <a class="local">'Topical corticosteroids'</a> above and <a class="local">'Hydroquinone'</a> above and <a class="local">'Mercury'</a> above.)</p><p class="headingAnchor" id="H1445813339"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Overview</strong> – Skin lightening (or skin bleaching) refers to the practice of using depigmenting agents to lighten the color of skin. Skin lightening is a global phenomenon that is most prevalent in Africa, Asia, the Caribbean, the Middle East, and Central/South America, as well as in immigrant populations in North America, Europe, and elsewhere. (See <a class="local">'Prevalence of skin lightening'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Agents</strong> – Skin-lightening agents associated with complications most commonly contain <a class="drug drug_general" data-topicid="8539" href="/d/drug information/8539.html" rel="external">hydroquinone</a>, mercury, corticosteroids, and caustic agents. Ingredient lists on packages are frequently inaccurate; in particular, products containing mercury may not list mercury as an ingredient. (See <a class="local">'Agents'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Complications</strong> – Use of skin-lightening agents may be associated with multiple cutaneous side effects, such as irritant contact dermatitis, exogenous ochronosis, cutaneous atrophy, and skin dyspigmentation. Serious systemic side effects, such as mercury toxicity, Cushing's disease, and adrenal crisis, can also occur. (See <a class="local">'Complications'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Recognition</strong> – Early recognition of the signs of misuse of skin-lightening agents is essential to prevent long-term or permanent local and/or systemic complications. Patients are often unaware that they are using products containing high-potency corticosteroids and other potentially harmful ingredients. (See <a class="local">'Recognition of at-risk patients'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Importance of cultural sensitivity</strong> – Inquiring about and counseling patients on use of skin-lightening agents should be performed with sensitivity. A variety of factors contribute to use of skin-lightening agents, and taking a nonjudgmental approach is valuable for communicating with patients. (See <a class="local">'Patient evaluation and management'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Management</strong> – The management of skin-lightening agent misuse consists of patient education, prompt discontinuation of the skin-lightening agent, and interventions to improve specific complications. In addition, patients with a history of excessive use of skin-lightening agents should be evaluated for mercury toxicity. (See <a class="local">'Interventions'</a> above.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Dadzie OE, Petit A. Skin bleaching: highlighting the misuse of cutaneous depigmenting agents. J Eur Acad Dermatol Venereol 2009; 23:741.</a></li><li><a class="nounderline abstract_t">Hamed SH, Tayyem R, Nimer N, Alkhatib HS. Skin-lightening practice among women living in Jordan: prevalence, determinants, and user's awareness. Int J Dermatol 2010; 49:414.</a></li><li><a class="nounderline abstract_t">Sagoe D, Pallesen S, Dlova NC, et al. The global prevalence and correlates of skin bleaching: a meta-analysis and meta-regression analysis. Int J Dermatol 2019; 58:24.</a></li><li><a class="nounderline abstract_t">Dlova NC, Hamed SH, Tsoka-Gwegweni J, Grobler A. Skin lightening practices: an epidemiological study of South African women of African and Indian ancestries. Br J Dermatol 2015; 173 Suppl 2:2.</a></li><li><a class="nounderline abstract_t">Lartey M, Krampa FD, Abdul-Rahman M, et al. Use of skin-lightening products among selected urban communities in Accra, Ghana. Int J Dermatol 2017; 56:32.</a></li><li><a class="nounderline abstract_t">Pollock S, Taylor S, Oyerinde O, et al. The dark side of skin lightening: An international collaboration and review of a public health issue affecting dermatology. Int J Womens Dermatol 2021; 7:158.</a></li><li><a class="nounderline abstract_t">Howard KL, Furner BB. Exogenous ochronosis in a Mexican-American woman. Cutis 1990; 45:180.</a></li><li><a class="nounderline abstract_t">Copan L, Fowles J, Barreau T, McGee N. Mercury Toxicity and Contamination of Households from the Use of Skin Creams Adulterated with Mercurous Chloride (Calomel). Int J Environ Res Public Health 2015; 12:10943.</a></li><li><a class="nounderline abstract_t">Centers for Disease Control and Prevention (CDC). Mercury poisoning associated with beauty cream--Texas, New Mexico, and California, 1995-1996. MMWR Morb Mortal Wkly Rep 1996; 45:400.</a></li><li><a class="nounderline abstract_t">Nagler A, Hale CS, Meehan SA, Leger M. Exogenous ochronosis. Dermatol Online J 2014; 20.</a></li><li><a class="nounderline abstract_t">Lawrence N, Bligard CA, Reed R, Perret WJ. Exogenous ochronosis in the United States. J Am Acad Dermatol 1988; 18:1207.</a></li><li><a class="nounderline abstract_t">Benn EKT, Deshpande R, Dotson-Newman O, et al. Skin Bleaching Among African and Afro-Caribbean Women in New York City: Primary Findings from a P30 Pilot Study. Dermatol Ther (Heidelb) 2019; 9:355.</a></li><li><a class="nounderline abstract_t">Al-Saleh I. Potential health consequences of applying mercury-containing skin-lightening creams during pregnancy and lactation periods. Int J Hyg Environ Health 2016; 219:468.</a></li><li class="breakAll">https://www.washingtonpost.com/politics/2019/06/15/dangerous-skin-bleaching-has-become-public-health-crisis-corporate-marketing-lies-behind-it/ (Accessed on January 24, 2022).</li><li><a class="nounderline abstract_t">Darj E, Infanti JJ, Ahlberg BM, Okumu J. "The fairer the better?" Use of potentially toxic skin bleaching products. Afr Health Sci 2015; 15:1074.</a></li><li><a class="nounderline abstract_t">Rusmadi SZ, Syed Ismail SN, Praveena SM. Preliminary study on the skin lightening practice and health symptoms among female students in Malaysia. J Environ Public Health 2015; 2015:591790.</a></li><li><a class="nounderline abstract_t">Ahmed AE, Hamid ME. Use of Skin-Whitening Products by Sudanese Undergraduate Females: a Survey. J Racial Ethn Health Disparities 2017; 4:149.</a></li><li><a class="nounderline abstract_t">James C, Seixas AA, Harrison A, et al. Childhood Physical and Sexual Abuse in Caribbean Young Adults and Its Association with Depression, Post-Traumatic Stress, and Skin Bleaching. J Depress Anxiety 2016; 5.</a></li><li><a class="nounderline abstract_t">Olumide YM, Akinkugbe AO, Altraide D, et al. Complications of chronic use of skin lightening cosmetics. Int J Dermatol 2008; 47:344.</a></li><li><a class="nounderline abstract_t">Dlova NC, Hendricks NE, Martincgh BS. Skin-lightening creams used in Durban, South Africa. Int J Dermatol 2012; 51 Suppl 1:51.</a></li><li class="breakAll">www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfCFR/CFRSearch.cfm?fr=700.13&amp;SearchTerm=mercury (Accessed on January 17, 2017).</li><li><a class="nounderline abstract_t">Hamann CR, Boonchai W, Wen L, et al. Spectrometric analysis of mercury content in 549 skin-lightening products: is mercury toxicity a hidden global health hazard? J Am Acad Dermatol 2014; 70:281.</a></li><li><a class="nounderline abstract_t">McKelvey W, Jeffery N, Clark N, et al. Population-based inorganic mercury biomonitoring and the identification of skin care products as a source of exposure in New York City. Environ Health Perspect 2011; 119:203.</a></li><li><a class="nounderline abstract_t">Ly F, Soko AS, Dione DA, et al. Aesthetic problems associated with the cosmetic use of bleaching products. Int J Dermatol 2007; 46 Suppl 1:15.</a></li><li><a class="nounderline abstract_t">Ladizinski B, Mistry N, Kundu RV. Widespread use of toxic skin lightening compounds: medical and psychosocial aspects. Dermatol Clin 2011; 29:111.</a></li><li><a class="nounderline abstract_t">Kramer KE, Lopez A, Stefanato CM, Phillips TJ. Exogenous ochronosis. J Am Acad Dermatol 2000; 42:869.</a></li><li><a class="nounderline abstract_t">Dogliotti M, Leibowitz M. Granulomatous ochronosis -- a cosmetic-induced skin disorder in Blacks. S Afr Med J 1979; 56:757.</a></li><li><a class="nounderline abstract_t">Findlay GH, Morrison JG, Simson IW. Exogenous ochronosis and pigmented colloid milium from hydroquinone bleaching creams. Br J Dermatol 1975; 93:613.</a></li><li><a class="nounderline abstract_t">Charlín R, Barcaui CB, Kac BK, et al. Hydroquinone-induced exogenous ochronosis: a report of four cases and usefulness of dermoscopy. Int J Dermatol 2008; 47:19.</a></li><li><a class="nounderline abstract_t">Romero SA, Pereira PM, Mariano AV, et al. Use of dermoscopy for diagnosis of exogenous ochronosis. An Bras Dermatol 2011; 86:S31.</a></li><li><a class="nounderline abstract_t">Levin CY, Maibach H. Exogenous ochronosis. An update on clinical features, causative agents and treatment options. Am J Clin Dermatol 2001; 2:213.</a></li><li><a class="nounderline abstract_t">Diven DG, Smith EB, Pupo RA, Lee M. Hydroquinone-induced localized exogenous ochronosis treated with dermabrasion and CO2 laser. J Dermatol Surg Oncol 1990; 16:1018.</a></li><li><a class="nounderline abstract_t">Bellew SG, Alster TS. Treatment of exogenous ochronosis with a Q-switched alexandrite (755 nm) laser. Dermatol Surg 2004; 30:555.</a></li><li><a class="nounderline abstract_t">Tan SK. Exogenous ochronosis - successful outcome after treatment with Q-switched Nd:YAG laser. J Cosmet Laser Ther 2013; 15:274.</a></li><li><a class="nounderline abstract_t">Camarasa JG, Serra-Baldrich E. Exogenous ochronosis with allergic contact dermatitis from hydroquinone. Contact Dermatitis 1994; 31:57.</a></li><li><a class="nounderline abstract_t">Petit A, Cohen-Ludmann C, Clevenbergh P, et al. Skin lightening and its complications among African people living in Paris. J Am Acad Dermatol 2006; 55:873.</a></li><li><a class="nounderline abstract_t">Garcia RL, White JW Jr, Willis WF. Hydroquinone nail pigmentation. Arch Dermatol 1978; 114:1402.</a></li><li><a class="nounderline abstract_t">Mann RJ, Harman RR. Nail staining due to hydroquinone skin-lightening creams. Br J Dermatol 1983; 108:363.</a></li><li><a class="nounderline abstract_t">Engler DE. Mercury "bleaching" creams. J Am Acad Dermatol 2005; 52:1113.</a></li><li><a class="nounderline abstract_t">Chan TY. Inorganic mercury poisoning associated with skin-lightening cosmetic products. Clin Toxicol (Phila) 2011; 49:886.</a></li><li><a class="nounderline abstract_t">Weldon MM, Smolinski MS, Maroufi A, et al. Mercury poisoning associated with a Mexican beauty cream. West J Med 2000; 173:15.</a></li><li><a class="nounderline abstract_t">Zhang L, Liu F, Peng Y, et al. Nephrotic syndrome of minimal change disease following exposure to mercury-containing skin-lightening cream. Ann Saudi Med 2014; 34:257.</a></li><li><a class="nounderline abstract_t">Tang HL, Chu KH, Mak YF, et al. Minimal change disease following exposure to mercury-containing skin lightening cream. Hong Kong Med J 2006; 12:316.</a></li><li><a class="nounderline abstract_t">Dickenson CA, Woodruff TJ, Stotland NE, et al. Elevated mercury levels in pregnant woman linked to skin cream from Mexico. Am J Obstet Gynecol 2013; 209:e4.</a></li><li><a class="nounderline abstract_t">Tempark T, Phatarakijnirund V, Chatproedprai S, et al. Exogenous Cushing's syndrome due to topical corticosteroid application: case report and review literature. Endocrine 2010; 38:328.</a></li><li><a class="nounderline abstract_t">Felten R, Messer L, Moreau P, et al. Osteonecrosis of the femoral head linked to topical steroids for skin bleaching: a case report. Ann Intern Med 2014; 161:763.</a></li></ol></div><div id="topicVersionRevision">Topic 110148 Version 5.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19470077" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Skin bleaching: highlighting the misuse of cutaneous depigmenting agents.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20465697" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Skin-lightening practice among women living in Jordan: prevalence, determinants, and user's awareness.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29888464" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : The global prevalence and correlates of skin bleaching: a meta-analysis and meta-regression analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26207658" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Skin lightening practices: an epidemiological study of South African women of African and Indian ancestries.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27943305" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Use of skin-lightening products among selected urban communities in Accra, Ghana.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33937483" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : The dark side of skin lightening: An international collaboration and review of a public health issue affecting dermatology.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2311433" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Exogenous ochronosis in a Mexican-American woman.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26364641" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Mercury Toxicity and Contamination of Households from the Use of Skin Creams Adulterated with Mercurous Chloride (Calomel).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8609883" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Mercury poisoning associated with beauty cream--Texas, New Mexico, and California, 1995-1996.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25526333" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Exogenous ochronosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3372785" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Exogenous ochronosis in the United States.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31020513" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Skin Bleaching Among African and Afro-Caribbean Women in New York City: Primary Findings from a P30 Pilot Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27009692" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Potential health consequences of applying mercury-containing skin-lightening creams during pregnancy and lactation periods.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27009692" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Potential health consequences of applying mercury-containing skin-lightening creams during pregnancy and lactation periods.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26958006" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : "The fairer the better?" Use of potentially toxic skin bleaching products.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26693230" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Preliminary study on the skin lightening practice and health symptoms among female students in Malaysia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26936463" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Use of Skin-Whitening Products by Sudanese Undergraduate Females: a Survey.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27019771" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Childhood Physical and Sexual Abuse in Caribbean Young Adults and Its Association with Depression, Post-Traumatic Stress, and Skin Bleaching.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18377596" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Complications of chronic use of skin lightening cosmetics.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23210963" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Skin-lightening creams used in Durban, South Africa.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23210963" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Skin-lightening creams used in Durban, South Africa.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24321702" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Spectrometric analysis of mercury content in 549 skin-lightening products: is mercury toxicity a hidden global health hazard?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20923743" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Population-based inorganic mercury biomonitoring and the identification of skin care products as a source of exposure in New York City.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17919199" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Aesthetic problems associated with the cosmetic use of bleaching products.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21095535" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Widespread use of toxic skin lightening compounds: medical and psychosocial aspects.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10767690" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Exogenous ochronosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/505210" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Granulomatous ochronosis -- a cosmetic-induced skin disorder in Blacks.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1220808" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Exogenous ochronosis and pigmented colloid milium from hydroquinone bleaching creams.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18173595" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Hydroquinone-induced exogenous ochronosis: a report of four cases and usefulness of dermoscopy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22068765" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Use of dermoscopy for diagnosis of exogenous ochronosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11705248" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Exogenous ochronosis. An update on clinical features, causative agents and treatment options.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2246407" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Hydroquinone-induced localized exogenous ochronosis treated with dermabrasion and CO2 laser.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15056151" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Treatment of exogenous ochronosis with a Q-switched alexandrite (755 nm) laser.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23464825" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Exogenous ochronosis - successful outcome after treatment with Q-switched Nd:YAG laser.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7924303" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Exogenous ochronosis with allergic contact dermatitis from hydroquinone.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17052496" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Skin lightening and its complications among African people living in Paris.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/686766" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Hydroquinone nail pigmentation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6219692" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Nail staining due to hydroquinone skin-lightening creams.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15928650" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Mercury "bleaching" creams.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22070559" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Inorganic mercury poisoning associated with skin-lightening cosmetic products.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10903281" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Mercury poisoning associated with a Mexican beauty cream.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25266189" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Nephrotic syndrome of minimal change disease following exposure to mercury-containing skin-lightening cream.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16912361" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Minimal change disease following exposure to mercury-containing skin lightening cream.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23685000" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Elevated mercury levels in pregnant woman linked to skin cream from Mexico.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20972726" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Exogenous Cushing's syndrome due to topical corticosteroid application: case report and review literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25402526" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Osteonecrosis of the femoral head linked to topical steroids for skin bleaching: a case report.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
